Which medications in the drug class Monoclonal Antibodies, Anti-asthmatics are used in the treatment of Linear IgA Dermatosis?

1. Zone JJ, Taylor TB, Meyer LJ, Petersen MJ. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol. 1998 Mar. 110(3):207-10. [Medline].

2. Zone JJ, Pazderka Smith E, Powell D, Taylor TB, Smith JB, Meyer LJ. Antigenic specificity of antibodies from patients with linear basement membrane deposition of IgA. Dermatology. 1994. 189 Suppl 1:64-6. [Medline].

3. Sakaguchi M, Bito T, Oda Y, et al. Three cases of linear IgA/IgG bullous dermatosis showing IgA and IgG reactivity with multiple antigens, particularly laminin-332. JAMA Dermatol. 2013 Nov. 149(11):1308-13. [Medline].

4. Zenke Y, Nakano T, Eto H, Koga H, Hashimoto T. A case of vancomycin-associated linear IgA bullous dermatosis and IgA antibodies to the a3 subunit of laminin-332. Br J Dermatol. 2014 Apr. 170(4):965-9. [Medline].

5. Nousari HC, Kimyai-Asadi A, Caeiro JP, Anhalt GJ. Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature. Medicine (Baltimore). 1999 Jan. 78(1):1-8. [Medline].

6. Nartker N, Kudlak N, Crowe D. Linear IgA bullous dermatosis protracted by vancomycin-loaded bone cement. JAAD Case Rep. 2019 Mar. 5 (3):234-236. [Medline].

7. Riemenschneider K, Diiorio DA, Zic JA, Livingood MR, Fine JD, Powers JG, et al. Drug-induced linear IgA bullous dermatosis in a patient with a vancomycin-impregnated cement spacer. Cutis. 2018 Apr. 101 (4):293-296. [Medline].

8. Sanke S, Kumar A, Chander R. Linear IgA bullous dermatosis induced by diclofenac sodium. Indian J Dermatol Venereol Leprol. 2018 Jul-Aug. 84 (4):496-497. [Medline].

9. Hoffmann J, Hadaschik E, Enk A, Stremmel W, Gauss A. Linear IgA Bullous Dermatosis Secondary to Infliximab Therapy in a Patient with Ulcerative Colitis. Dermatology. 2015. 231 (2):112-5. [Medline].

10. Jonna S, Neiders M, Lakshmanan S, Khan A, DeKlotz T, Lanasa D, et al. Linear IgA Disease of the Gingiva Following Nivolumab Therapy. J Immunother. 2019 Nov/Dec. 42 (9):345-347. [Medline].

11. Alberta-Wszolek L, Mousette AM, Mahalingam M, Levin NA. Linear IgA bullous dermatosis following influenza vaccination. Dermatol Online J. 2009 Nov 15. 15(11):3. [Medline].

12. Yhim HY, Kwon DH, Lee NR, Song EK, Yim CY, Kwak JY. Linear IgA bullous dermatosis following autologous PBSC transplantation in a patient with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2010 Apr 12. [Medline].

13. Godfrey K, Wojnarowska F, Leonard J. Linear IgA disease of adults: association with lymphoproliferative malignancy and possible role of other triggering factors. Br J Dermatol. 1990 Oct. 123(4):447-52. [Medline].

14. Colmant C, Camboni A, Dekeuleneer V, Marot L, Dachelet C, Baeck M. Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: A case report with literature review. J Cutan Pathol. 2020 Mar. 47 (3):251-256. [Medline].

15. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995 Jan. 131(1):48-52. [Medline].

16. Kharfi M, Khaled A, Karaa A, Zaraa I, Fazaa B, Kamoun MR. Linear IgA bullous dermatosis: the more frequent bullous dermatosis of children. Dermatol Online J. 2010 Jan 15. 16(1):2. [Medline].

17. Chanal J, Ingen-Housz-Oro S, Ortonne N, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013 Nov. 169(5):1041-8. [Medline].

18. Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol. 1988 Nov. 19(5 Pt 1):792-805. [Medline].

19. Collier PM, Kelly SE, Wojnarowska F. Linear IgA disease and pregnancy. J Am Acad Dermatol. 1994 Mar. 30(3):407-11. [Medline].

20. Bakke JR, Chantara A, Cash J, Fisher KR. Vancomycin-induced linear IgA bullous dermatosis presenting as generalized fixed drug eruption. J Cutan Pathol. 2019 Dec. 46 (12):979-981. [Medline].

21. Billet SE, Kortuem KR, Gibson LE, El-Azhary R. A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis. Arch Dermatol. 2008 Jun. 144(6):774-8. [Medline].

22. Choudhry SZ, Kashat M, Lim HW. Vancomycin-induced linear IgA bullous dermatosis demonstrating the isomorphic phenomenon. Int J Dermatol. 2015 Nov. 54 (11):1211-3. [Medline].

23. Chan LS, Regezi JA, Cooper KD. Oral manifestations of linear IgA disease. J Am Acad Dermatol. 1990 Feb. 22(2 Pt 2):362-5. [Medline].

24. Aultbrinker EA, Starr MB, Donnenfeld ED. Linear IgA disease. The ocular manifestations. Ophthalmology. 1988 Mar. 95(3):340-3. [Medline].

25. El-Domyati M, Abdel-Wahab H, Ahmad H. Immunohistochemical localization of basement membrane laminin 5 and collagen IV in adult linear IgA disease. Int J Dermatol. 2015 Aug. 54 (8):922-8. [Medline].

26. Tomida E, Kato Y, Ozawa H, Hasegawa H, Ishii N, Hashimoto T, et al. Causative drug detection by drug-induced lymphocyte stimulation test in drug-induced linear IgA bullous dermatosis. Br J Dermatol. 2015 Aug 12. [Medline].

27. Krejci-Manwaring J, West DA, Tonkovic-Capin V. If at first you don't succeed: a difficult case of Linear IgA. Dermatol Online J. 2009 Sep 15. 15(9):16. [Medline].

28. Tieppo Francio V, Towery C, Davani S, Allen T, Brown TL. Previously misdiagnosed linear IgA dermatosis resolved with dapsone. BMJ Case Rep. 2018 Apr 25. 2018:[Medline].

29. Jablonska S, Chorzelski TP, Rosinska D, Maciejowska E. Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood). Clin Dermatol. 1991 Jul-Sep. 9(3):393-401. [Medline].

30. Yang Z, Liu ZH, Sun CQ, Shen H. Successful treatment of a case of idiopathic linear IgA bullous dermatosis with oral sulfasalazine. Dermatol Ther. 2020 Jan 2. e13210. [Medline].

31. Maalouf NS, Hanna D. Linear IgA bullous dermatosis successfully treated with omalizumab: A case report. JAAD Case Rep. 2019 Nov. 5 (11):966-969. [Medline].

32. Shan XF, Zhang FR, Tian HQ, Wang N, Zhou SJ, Wang GJ. A case of linear IgA dermatosis successfully treated with tetracycline and niacinamide. Int J Dermatol. 2015 Dec 23. [Medline].

33. Lozinski A, Baum S, Sagi L, Volkov A, Trau H, Barzilai A. [Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders]. Harefuah. 2012 Oct. 151 (10):562-5, 606. [Medline].

34. Norris IN, Haeberle MT, Callen JP, Malone JC. Generalized linear IgA dermatosis with palmar involvement. Dermatol Online J. 2015 Sep 17. 21 (9):[Medline].

35. Kaya İslamoğlu ZG, Akyürek FT. A case of recalcitrant linear IgA bullous dermatosis: Successfully treated with rituximab. Dermatol Ther. 2019 May. 32 (3):e12911. [Medline].

36. Pinard C, Hebert V, Lecuyer M, Sacre L, Joly P. Linear IgA bullous dermatosis treated with rituximab. JAAD Case Rep. 2019 Feb. 5 (2):124-126. [Medline].

37. Klein PA, Callen JP. Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency. J Am Acad Dermatol. 2000 Feb. 42(2 Pt 2):316-23. [Medline].

Mark Tye Haeberle, MD Assistant Clinical Faculty, Division of Dermatology, University of Louisville School of Medicine

Mark Tye Haeberle, MD is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, American Society of Dermatopathology, International Society of Dermatopathology

Disclosure: Received income in an amount equal to or greater than $250 from: UpToDate.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Allergen; Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Society for Investigative Dermatology, Association of Professors of Dermatology, North American Hair Research Society

Disclosure: Nothing to disclose.

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Russell Hall, MD J Lamar Callaway Professor And Chair, Department of Dermatology, Duke University Medical Center, Duke University School of Medicine

Russell Hall, MD is a member of the following medical societies: American Academy of Dermatology, American Federation for Medical Research, American Society for Clinical Investigation, Society for Investigative Dermatology

Disclosure: Received consulting fee from Novan for consulting; Received consulting fee from Stieffel, a GSK company for consulting; Received salary from Society for Investigative Dermatology for board membership.

Peter A Klein, MD Associate Professor, Department of Dermatology, University Hospital, State University of New York at Stony Brook

Disclosure: Nothing to disclose.